Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PPM1D | O15297 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307043 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL20696859 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL3735009 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL7261027 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL3735003 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL24677027 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL12629186 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL29754849 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL31748003 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL30152746 | 0.96 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630420-A1 | INHIBITORS OF NLRP3 | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121184-A1 | INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-11-04 | — | — | US | disclosed |
| WO-2003051877-A1 | 2-SUBSTITUTED PYRROLO[2.1-A]ISOQUINOLINES AGAINST CANCER | BAYER CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280238-A1 | INTRAMOLECULAR AZIDE-ALKYNE CYCLOADDITION | APOBEC3G, HYOU1, HTR3C | THRB 1497/4885MEN1 1158/4885KMT2A 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.